Effect of phosphodiesterase inhibitors in the bladder

Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cystei...

Full description

Saved in:
Bibliographic Details
Main Authors: Bilal Chughtai, Aizaz Ali, Claire Dunphy, Steven A. Kaplan
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Asian Journal of Urology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388215000387
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850243807742787584
author Bilal Chughtai
Aizaz Ali
Claire Dunphy
Steven A. Kaplan
author_facet Bilal Chughtai
Aizaz Ali
Claire Dunphy
Steven A. Kaplan
author_sort Bilal Chughtai
collection DOAJ
description Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cysteine/H2S pathway. PDE5 inhibitors exert their effect in muscle cells, nerve fibers, and interstitial cells (ICs). The use of PDE5 inhibitors led to improvement in LUTS. This included urodynamic parameters. PDE5 inhibitors may play a significant role in LUTS due to their effect on the bladder rather than the prostate.
format Article
id doaj-art-ae9bb15c5fe640eab6ad84fb0e8a99c0
institution OA Journals
issn 2214-3882
language English
publishDate 2015-01-01
publisher Elsevier
record_format Article
series Asian Journal of Urology
spelling doaj-art-ae9bb15c5fe640eab6ad84fb0e8a99c02025-08-20T01:59:53ZengElsevierAsian Journal of Urology2214-38822015-01-0121333710.1016/j.ajur.2015.04.014Effect of phosphodiesterase inhibitors in the bladderBilal ChughtaiAizaz AliClaire DunphySteven A. KaplanMany aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cysteine/H2S pathway. PDE5 inhibitors exert their effect in muscle cells, nerve fibers, and interstitial cells (ICs). The use of PDE5 inhibitors led to improvement in LUTS. This included urodynamic parameters. PDE5 inhibitors may play a significant role in LUTS due to their effect on the bladder rather than the prostate.http://www.sciencedirect.com/science/article/pii/S2214388215000387Lower urinary tract symptoms (LUTS)Overactive bladder syndrome (OAB)Phosphodiesterase type 5 inhibitorsNO/cGMPcAMP
spellingShingle Bilal Chughtai
Aizaz Ali
Claire Dunphy
Steven A. Kaplan
Effect of phosphodiesterase inhibitors in the bladder
Asian Journal of Urology
Lower urinary tract symptoms (LUTS)
Overactive bladder syndrome (OAB)
Phosphodiesterase type 5 inhibitors
NO/cGMP
cAMP
title Effect of phosphodiesterase inhibitors in the bladder
title_full Effect of phosphodiesterase inhibitors in the bladder
title_fullStr Effect of phosphodiesterase inhibitors in the bladder
title_full_unstemmed Effect of phosphodiesterase inhibitors in the bladder
title_short Effect of phosphodiesterase inhibitors in the bladder
title_sort effect of phosphodiesterase inhibitors in the bladder
topic Lower urinary tract symptoms (LUTS)
Overactive bladder syndrome (OAB)
Phosphodiesterase type 5 inhibitors
NO/cGMP
cAMP
url http://www.sciencedirect.com/science/article/pii/S2214388215000387
work_keys_str_mv AT bilalchughtai effectofphosphodiesteraseinhibitorsinthebladder
AT aizazali effectofphosphodiesteraseinhibitorsinthebladder
AT clairedunphy effectofphosphodiesteraseinhibitorsinthebladder
AT stevenakaplan effectofphosphodiesteraseinhibitorsinthebladder